menu
    • menu
    [{"orgOrder":0,"company":"Corsera Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"COR-1004","moa":"PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsera Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Corsera Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corsera Health \/ Undisclosed"},{"orgOrder":0,"company":"Corsera Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"COR-1004","moa":"PCSK9 | AGT","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsera Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Corsera Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corsera Health \/ Undisclosed"},{"orgOrder":0,"company":"Corsera Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"COR-1004","moa":"AGT | PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Corsera Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Corsera Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Corsera Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Corsera Health

    Menu

    Corsera Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Corsera Health

                            India arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Corsera Health

                            India arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COR-1004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate COR-1004 in Adult Volunteers.

                            Details : COR-1004 is a oligonucleotide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Hyperlipidemias.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            November 14, 2025

                            Lead Product(s) : COR-1004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Corsera Health

                            India arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Corsera Health

                            India arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COR-1004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Corsera Health Files Phase 1 Trial for Preventive RNAi Medicine in Cardiovascular Disease

                            Details : COR-1004, an oligonucleotide targeting PCSK9, shows promise in reducing high LDL cholesterol levels, a key focus area in cardiovascular health.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 27, 2025

                            Lead Product(s) : COR-1004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Corsera Health

                            India arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Corsera Health

                            India arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : COR-1004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Corsera Health Files Phase 1 Trial for Preventive RNAi Medicine in Cardiovascular Disease

                            Details : COR-1004, an oligonucleotide, targets PCSK9 and AGT to address cardiovascular disease.

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            October 27, 2025

                            Lead Product(s) : COR-1004

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth